Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Abbvie Inc (NYSE: ABBV) closed the day trading at $161.52 up 1.19% from the previous closing price of $159.62. In other words, the price has increased by $1.19 from its previous closing price. On the day, 6.22 million shares were traded. ABBV stock price reached its highest trading level at $161.55 during the session, while it also had its lowest trading level at $158.56.
Ratios:
For a better understanding of ABBV, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 22.32 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.99. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 0.87. In the meantime, Its Debt-to-Equity ratio is 5.80 whereas as Long-Term Debt/Eq ratio is at 5.11.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 20 ’24 when Donoghoe Nicholas sold 21,082 shares for $176.30 per share. The transaction valued at 3,716,757 led to the insider holds 55,903 shares of the business.
Stewart Jeffrey Ryan sold 58,949 shares of ABBV for $10,539,508 on Mar 18 ’24. The EVP, CHIEF COMMERCIAL OFFICER now owns 60,941 shares after completing the transaction at $178.79 per share. On Mar 01 ’24, another insider, RICHMOND TIMOTHY J., who serves as the EVP, CHIEF HR OFFICER of the company, sold 75,680 shares for $177.27 each. As a result, the insider received 13,415,503 and left with 13,837 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABBV now has a Market Capitalization of 285995401216 and an Enterprise Value of 333120765952. As of this moment, Abbvie’s Price-to-Earnings (P/E) ratio for their current fiscal year is 48.01, and their Forward P/E ratio for the next fiscal year is 13.37. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 7.57. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.26 while its Price-to-Book (P/B) ratio in mrq is 27.53. Its current Enterprise Value per Revenue stands at 6.123 whereas that against EBITDA is 12.395.
Stock Price History:
The Beta on a monthly basis for ABBV is 0.59, which has changed by 0.06529486 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, ABBV has reached a high of $182.89, while it has fallen to a 52-week low of $130.96. The 50-Day Moving Average of the stock is -7.43%, while the 200-Day Moving Average is calculated to be 3.00%.
Shares Statistics:
Over the past 3-months, ABBV traded about 5.71M shares per day on average, while over the past 10 days, ABBV traded about 5580410 shares per day. A total of 1.77B shares are outstanding, with a floating share count of 1.77B. Insiders hold about 0.11% of the company’s shares, while institutions hold 71.55% stake in the company. Shares short for ABBV as of 1713139200 were 13536080 with a Short Ratio of 2.37, compared to 1710460800 on 14691308. Therefore, it implies a Short% of Shares Outstanding of 13536080 and a Short% of Float of 0.77.
Dividends & Splits
ABBV’s forward annual dividend rate is 6.06, up from 6.06 a year ago. Against a Trailing Annual Dividend Yield of 0.037965167The stock’s 5-year Average Dividend Yield is 4.42.
Earnings Estimates
The current market rating for Abbvie Inc (ABBV) reflects the collective analysis of 15.0 analysts closely monitoring its performance.On average, analysts expect EPS of $2.86 for the current quarter, with a high estimate of $3.06 and a low estimate of $2.62, while EPS last year was $2.91. The consensus estimate for the next quarter is $2.93, with high estimates of $3.04 and low estimates of $2.81.
Analysts are recommending an EPS of between $11.37 and $10.86 for the fiscal current year, implying an average EPS of $11.13. EPS for the following year is $12.17, with 24.0 analysts recommending between $13.22 and $11.46.
Revenue Estimates
15 analysts predict $13.72B in revenue for the current quarter. It ranges from a high estimate of $14.2B to a low estimate of $12.99B. As of the current estimate, Abbvie Inc’s year-ago sales were $13.87BFor the next quarter, 15 analysts are estimating revenue of $14.14B. There is a high estimate of $14.37B for the next quarter, whereas the lowest estimate is $13.88B.
A total of 25 analysts have provided revenue estimates for ABBV’s current fiscal year. The highest revenue estimate was $55.76B, while the lowest revenue estimate was $53.86B, resulting in an average revenue estimate of $54.74B. In the same quarter a year ago, actual revenue was $54.32BBased on 25 analysts’ estimates, the company’s revenue will be $57.96B in the next fiscal year. The high estimate is $60.8B and the low estimate is $55.72B.
